Direct compression of cefalexin monohydrate at 500 mg active strength is run on a Korsch XL 400 high-speed rotary press with 10 mm round shallow-concave B-tooling. The monohydrate powder is pre-blended in a 600 L bin blender with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and colloidal silicon dioxide before magnesium stearate is added as a terminal lubricant. Batch-to-batch changes in D[4,3] laser diffraction particle size per USP ‹429› have been observed in production campaigns to shift tablet hardness at constant press speed, particularly when the D90 exceeds the aperture of the screen used before blending. A 20-mesh screen is therefore placed immediately upstream of the blender. Tablet weight is monitored by an automatic checkweigher linked to the press fill cam, and hardness is tested on a 10-station testing unit. Direct compression is constrained by poor powder flow, so the formulation is adjusted with colloidal silicon dioxide in the range of 0.5–1.0% w/w and magnesium stearate not above 1.0% w/w because over-lubrication retards dissolution in USP ‹711› testing. When compression force is raised above 12 kN, capping and lamination have been observed on 10 mm tooling at press speeds above 60 rpm. These failures are controlled by reducing precompression force and maintaining tablet friability below 0.8% as described in USP ‹1216›. The batch is not permitted to proceed to compression if loss on drying by USP ‹731› exceeds the cefalexin monohydrate release specification; elevated moisture increases the risk of picking and sticking on punch faces. Precompression force is maintained below 3 kN when capping begins, and main compression force is then increased in 1 kN increments until the capping threshold is confirmed. Content uniformity is assessed at compression start-up, middle, and end using stratified sampling; acceptance limits follow USP ‹905›. Published data for this exact direct compression configuration is limited; each batch is therefore qualified against the cefalexin tablet monograph for assay, related substances and dissolution.

The pharmacopoeial controls required to keep downstream processing within validated limits are shown below.

Which Flow and Retention Factors Control Cefalexin Capsule Filling on Dosing Disc Machines?

On dosing disc-type capsule fillers, cefalexin monohydrate blends are often converted into low-fines granules by slugging before encapsulation. Slugs are produced on a rotary press with 12 mm flat-faced punches and passed through a 14-mesh screen. The granule fraction between 840 µm and 150 µm is preferentially used to reduce hopper segregation. Capsule fill weight is controlled by the dosing disc height and the powder bed depth; on an MG2 continuous motion capsule filler, bed height variation greater than ±2 mm has been observed to increase fill weight RSD above 2.0%. The capsule body is filled into hard gelatin or HPMC capsules size 0 or size 1, depending on bulk density. Tamping station frequency and pin force are adjusted so that plug density falls between 0.60 g/mL and 0.75 g/mL; lower plug density causes ejection leakage, while higher plug density may delay shell disintegration. Capsule disintegration is checked per USP ‹701› and dissolution per USP ‹711›. The capsule shell water content is not adjusted with a desiccant until the finished pack moisture has been confirmed under 25 °C/60% RH storage conditions consistent with ICH Q1A. Published data for cefalexin capsule retention on specific machine models is limited; validation batches are required to set the acceptable fill weight range and the maximum hopper hold time.

Low-Shear Mixing Before Roller Compaction Limits Cefalexin Degradation

Dry granulation by roller compaction is used when direct compression fails flow or content uniformity. The pre-blend is discharged from a bin blender through a rotary valve into a roller compactor with roll force set to produce ribbon porosity that can be milled without generating excess fines. Ribbons are milled through a 1.0 mm screen, and the granules are re-blended with disintegrant before lubrication. The disintegrant is split half intragranular and half extragranular to maintain tablet disintegration after compression. Roller compaction reduces the volume median particle size but increases the fines fraction if the roll surface is worn; this shifts the granule-to-excipient ratio and can change content uniformity. The granulation endpoint is monitored by bulk density using USP ‹616› and by sieve analysis. Wet aqueous granulation is generally avoided for cefalexin monohydrate because the beta-lactam ring hydrolyses in the presence of water and heat, reducing assay and increasing related substances. Drying after any aqueous granulation is completed to a loss on drying below 2.0% per USP ‹731›. Compression of roller-compacted granules is then performed on a 16-station rotary press at reduced speed until the capping threshold is confirmed. Published data for this specific cefalexin roller compaction configuration is limited; process capability is established on pilot batches before scale-up.

Dry syrup formulations of cefalexin for reconstitution to 125 mg/5 mL and 250 mg/5 mL are processed as free-flowing granules rather than simple powder blends. The granulation is built in a high-shear mixer or fluid-bed granulator using a binder solution; water activity in the wet mass is kept low to limit beta-lactam hydrolysis. Drying in a fluid-bed dryer is completed to a loss on drying below 2.0% per USP ‹731›. The dried granulation is passed through a 16-mesh screen and blended with sucrose, xanthan gum, sodium benzoate and flavour before powder filling into amber glass or HDPE bottles. The bulk density of the dry syrup is kept above 0.50 g/mL to provide a reproducible fill volume and to reduce settling during transport. The reconstituted suspension pH is commonly adjusted to 4.0–5.5; pH is tested per USP ‹791› and is controlled because cefalexin hydrolysis is slower in mildly acidic media and because sodium benzoate efficacy depends on the undissociated acid fraction. Filling of the dry powder is performed with an auger filler and fill weight is checked per USP ‹905›. After reconstitution, the product licence storage statement is typically 7–14 days under refrigeration, but this must be confirmed by the stability protocol of the specific marketing authorization. The critical process limit is moisture content at bottle sealing: if residual moisture rises above the validated limit, the beta-lactam ring opens during storage, producing yellow-brown discolouration and measurable loss of potency. Published multi-batch data for cefalexin dry syrup ageing at 40 °C/75% RH are limited; each formulation is qualified under ICH stability zones and stress conditions required by the target market.

When Cefalexin Monohydrate Is Dry-Blended for Sachet Filling, Bulk Density and Segregation Govern Fill Weight Uniformity

Unit-dose sachet filling of cefalexin granules is governed by bulk density and sieve fraction consistency per USP ‹616› and USP ‹429›; in-line checkweighing must be set tighter than bulk bottle fill limits because each sachet is a single unit dose tested under USP ‹905›.

Injectable Cefalexin Formulation Screening and Monograph Constraints

Injectable cefalexin is not a harmonized compendial dosage form in USP, Ph.Eur., or JP. Published data for parenteral cefalexin formulation is limited, and cefalexin monohydrate is not the salt form normally selected for intravenous injection. A development project requiring an injectable cefalexin formulation must begin with pH-dependent solubility screening, compatibility with tonicity-adjusting agents, and forced-degradation studies on the reconstituted solution. The beta-lactam ring of cefalexin hydrolyses in aqueous solution, with the rate accelerating below pH 3 and above pH 7; published data for this specific configuration is limited, so the developer must establish a stability-indicating assay and related substances limits before batch manufacture. Container closure system and lighting conditions must be controlled because cephalosporins are light-sensitive in solution. Injection products require sterility assurance under USP ‹71›, bacterial endotoxin testing under USP ‹85›, and particulate matter control under USP ‹788›. These tests must be incorporated into the release specification. Without published stability data for cefalexin injectable formulations, terminal sterilization and membrane filtration strategies cannot be selected without experimental validation.